427 related articles for article (PubMed ID: 30504427)
1. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
[TBL] [Abstract][Full Text] [Related]
2. MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
Yip C; Foidart P; Somja J; Truong A; Lienard M; Feyereisen E; Schroeder H; Gofflot S; Donneau AF; Collignon J; Delvenne P; Sounni NE; Jerusalem G; Noël A
Br J Cancer; 2017 Mar; 116(6):742-751. PubMed ID: 28196064
[TBL] [Abstract][Full Text] [Related]
3. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Yamamoto T; Kanaya N; Somlo G; Chen S
Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
[TBL] [Abstract][Full Text] [Related]
5. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
[No Abstract] [Full Text] [Related]
7. EGFR activation and signaling in cancer cells are enhanced by the membrane-bound metalloprotease MT4-MMP.
Paye A; Truong A; Yip C; Cimino J; Blacher S; Munaut C; Cataldo D; Foidart JM; Maquoi E; Collignon J; Delvenne P; Jerusalem G; Noel A; Sounni NE
Cancer Res; 2014 Dec; 74(23):6758-70. PubMed ID: 25320013
[TBL] [Abstract][Full Text] [Related]
8. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
[TBL] [Abstract][Full Text] [Related]
10. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.
Arnedos M; Bayar MA; Cheaib B; Scott V; Bouakka I; Valent A; Adam J; Leroux-Kozal V; Marty V; Rapinat A; Mazouni C; Sarfati B; Bieche I; Balleyguier C; Gentien D; Delaloge S; Lacroix-Triki M; Michiels S; Andre F
Ann Oncol; 2018 Aug; 29(8):1755-1762. PubMed ID: 29893769
[TBL] [Abstract][Full Text] [Related]
12. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
Zhou Y; Jin X; Ma J; Ding D; Huang Z; Sheng H; Yan Y; Pan Y; Wei T; Wang L; Wu H; Huang H
Cancer Res; 2021 Mar; 81(6):1486-1499. PubMed ID: 33419772
[TBL] [Abstract][Full Text] [Related]
13. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway.
Ma Y; Fang Z; Zhang H; Qi Y; Mao Y; Zheng J
Cell Death Dis; 2024 Apr; 15(3):199. PubMed ID: 38604999
[TBL] [Abstract][Full Text] [Related]
14. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
[TBL] [Abstract][Full Text] [Related]
15. Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.
Anborgh PH; Lee DJ; Stam PF; Tuck AB; Chambers AF
Expert Opin Ther Targets; 2018 Aug; 22(8):727-734. PubMed ID: 30025479
[TBL] [Abstract][Full Text] [Related]
16. HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.
Chen F; Zhang Z; Yu Y; Liu Q; Pu F
Int J Oncol; 2020 Jul; 57(1):223-236. PubMed ID: 32377705
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
[TBL] [Abstract][Full Text] [Related]
18. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
Dávila-González D; Choi DS; Rosato RR; Granados-Principal SM; Kuhn JG; Li WF; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Clin Cancer Res; 2018 Mar; 24(5):1152-1162. PubMed ID: 29301832
[No Abstract] [Full Text] [Related]
20. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
